Clinicopatological features and outcome of breast cancer in CHEK2 germline mutation carriers

被引：0
|
作者：
Schlosser, Shir
Molho, Rinat Bernstein
Karminsky, Natalia
Barsuk, Daphna
Goldberg, Yael
Friedman, Eitan
Yerushalmi, Rinat
Drumea, Keren
Kedar, Inbal
Jiveliouk, Irina
Ben David, Merav Akiva
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-09-16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-09-16
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.
    Scott, Danika
    Kingham, Kerry
    Hodan, Rachel
    Ma, Cindy
    Mills, Meredith
    Ford, James M.
    Kurian, Allison W.
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Chromosomal radio sensitivity of breast cancer with a CHEK2 mutation
    Baeyens, A
    Claes, K
    Willems, P
    De Ruyck, K
    Thierens, H
    Vral, A
    CANCER GENETICS AND CYTOGENETICS, 2005, 163 (02) : 106 - 112
  • [23] Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer
    Ansari, Narges
    Shahrabi, Saeid
    Khosravi, Abbas
    Shirzad, Reza
    Rezaeean, Hadi
    LABORATORY MEDICINE, 2019, 50 (03) : E36 - E41
  • [24] Papillary thyroid cancer in a patient with germline CHEK2 mutation: A case report
    da Silva Santos, Tiago
    Tkachenko, Nataliya
    de Carvalho, Andre Couto
    ANNALES D ENDOCRINOLOGIE, 2021, 82 (06) : 624 - 626
  • [25] Breast Cancer Risk in Familial CHEK2 Germline Mutation Carriers is Modified by the Polygenic Risk Score: A Multicenter Study by the German Consortium for Hereditary Breast and Ovarian Cancer
    Borde, Julika
    Ernst, Corinna
    Weber-Lassalle, Konstantin
    Niederacher, Dieter
    Hauke, Jan
    Horvath, Judit
    Weber-Lassalle, Nana
    Meindl, Alfons
    Bernd, Auber
    Pohl-Rescigno, Esther
    Arnold, Norbert
    Lee, Andrew
    Engel, Christoph
    Wappenschmidt, Barbara
    Schmidt, Marjanka
    Antoniou, Antonis
    Schmutzler, Rita Katharina
    Kuchenbaecker, Karoline
    Hahnen, Eric
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 20 - 21
  • [26] Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers
    Pohl, E.
    Borde, J.
    Hauke, J.
    Schmidt, S.
    Weber-Lassalle, K.
    Ernst, C.
    Niederacher, D.
    Arnold, N.
    Hellebrand, H.
    Meindl, A.
    Gehrig, A.
    Schmidt, G.
    Dutrannoy, V.
    Kast, K.
    Hahnen, E.
    Schmutzler, R.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 535 - 536
  • [27] Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
    Mieke Kriege
    Agnes Jager
    Antoinette Hollestelle
    Els M. J. J. Berns
    Jannet Blom
    Marion E. Meijer-van Gelder
    Anieta M. Sieuwerts
    Ans van den Ouweland
    J. Margriet Collée
    Judith R. Kroep
    John W. M. Martens
    Maartje J. Hooning
    Caroline Seynaeve
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1879 - 1887
  • [28] Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers
    Pfeifer, Werner
    Sokolenko, Anna P.
    Potapova, Olga N.
    Bessonov, Alexandr A.
    Ivantsov, Alexandr O.
    Laptiev, Sergey A.
    Zaitseva, Olga A.
    Yatsuk, Olga S.
    Matsko, Dmitry E.
    Semiglazova, Tatiana Yu.
    Togo, Alexandr V.
    Imyanitov, Evgeny N.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (03) : 675 - 683
  • [29] Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers
    Werner Pfeifer
    Anna P. Sokolenko
    Olga N. Potapova
    Alexandr A. Bessonov
    Alexandr O. Ivantsov
    Sergey A. Laptiev
    Olga A. Zaitseva
    Olga S. Yatsuk
    Dmitry E. Matsko
    Tatiana Yu. Semiglazova
    Alexandr V. Togo
    Evgeny N. Imyanitov
    Breast Cancer Research and Treatment, 2014, 148 : 675 - 683
  • [30] Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers
    Pohl, E.
    Richters, L.
    Hauke, J.
    Ernst, C.
    Krober, S.
    Niederacher, D.
    Arnold, N.
    Ramser, J.
    Gross, E.
    Gehrig, A.
    Schmidt, G.
    Dutrannoy, V.
    Kast, K.
    Hahnen, E.
    Schmutzler, R.
    CANCER RESEARCH, 2017, 77
12345